Condition: Dravet Syndrome · Sponsor: Ionis Pharmaceuticals, Inc.
The primary purpose of this study is to evaluate the safety and tolerability of ION337 in participants with Dravet syndrome (DS).
This description comes directly from the study's public registry record.
Ionis Pharmaceuticals, Inc. · (844) 867-4309 · IonisDravetSyndrome@clinicaltrialmedia.com
Always discuss trial participation with your own doctor first.
| University of Michigan Health System | Ann Arbor, Michigan, United States | Recruiting |
| Mayo Clinic | Rochester, Minnesota, United States | Recruiting |
| Le Bonheur Children's Hospital | Memphis, Tennessee, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07531745